Clinical trialNCT06725758RecruitingPhase 1/PHASE2Interventional

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

SponsorOrion Corporation, Orion PharmaEnrollment315Solid Tumours

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Clinical Study Director
Orion Corporation, Orion Pharma
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Finland

Helsinki University Hospital
Helsinki, Finland
Katriina Jalkanen, MD
Recruiting
Oulu University Hospital
Oulu, Finland
Jussi Koivunen, MD
Recruiting
Turku University Hospital
Turku, Finland
Panu Jaakkola, MD
Recruiting

France

Institut Bergonie
Bordeaux, France
Antoine Italiano, MD
Recruiting
Centre Oscar Lambret
Lille, France
Loic Lebellec, MD
Recruiting
Institut Gustave Roussy
Villejuif, France
Yohann Loriot, MD
Recruiting

Spain

Hospital 12 de Octubre
Madrid, Spain
Jon Zugazagoitia, MD
Recruiting
Hospital Virgen de la Macarena
Seville, Spain
David Vicente, MD
Recruiting

Switzerland

Istituto Oncologico, Ospedale Bellinzona E Valli
Bellinzona, Canton Ticino, Switzerland
Ilaria Colombo, MD
Recruiting

United Kingdom

Leicester Royal Infirmary
Leicester, United Kingdom
Harriet Walter, MD
Recruiting
Royal Marsden Hospital, London, Uk
London, United Kingdom
Johann de Bono, MD
Recruiting
Weston Park Hospital
Sheffield, United Kingdom
Sarah Danson, MD
Recruiting

United States

Valkyrie Clinical Trials
Los Angeles, California, United States
David Berz, MD
Recruiting
Uc Irvine Health
Orange, California, United States
Farshid Dayyani, MD
Recruiting
Siteman Cancer Center
St Louis, Missouri, United States
Ayse Daylan, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Mrinal Gounder, MD
Recruiting
Westchester Medical Center
Valhalla, New York, United States
Marjorie Zauderer, MD
Recruiting
Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Sarah Gordon, MD
Recruiting
University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Vinod Ravi, MD
Recruiting
Next Virginia
Fairfax, Virginia, United States
Alexander Spira, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

M32Knf9wdv

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Oct 2023
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 8 May 2026
Registered enrollment: 315
Registry id: NCT06725758

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-503061-29-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.